Compare ARE & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARE | RGEN |
|---|---|---|
| Founded | 1994 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 8.1B |
| IPO Year | 1997 | 1995 |
| Metric | ARE | RGEN |
|---|---|---|
| Price | $49.51 | $117.44 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 11 |
| Target Price | $58.11 | ★ $173.09 |
| AVG Volume (30 Days) | ★ 1.7M | 849.0K |
| Earning Date | 04-27-2026 | 04-28-2026 |
| Dividend Yield | ★ 9.69% | N/A |
| EPS Growth | N/A | ★ 286.96 |
| EPS | N/A | ★ 0.86 |
| Revenue | ★ $3,026,556,000.00 | $141,236,000.00 |
| Revenue This Year | N/A | $14.11 |
| Revenue Next Year | $0.52 | $14.71 |
| P/E Ratio | ★ N/A | $136.91 |
| Revenue Growth | N/A | ★ 35.10 |
| 52 Week Low | $44.10 | $102.97 |
| 52 Week High | $98.27 | $175.77 |
| Indicator | ARE | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 41.62 | 36.65 |
| Support Level | $49.38 | $112.97 |
| Resistance Level | $54.86 | $132.51 |
| Average True Range (ATR) | 1.76 | 4.80 |
| MACD | -0.27 | 0.42 |
| Stochastic Oscillator | 25.88 | 35.92 |
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.